Acceleron Pharma (XLRN)

178.75  -0.93 (-0.52%)

After market: 179.92 +1.17 (+0.65%)

Fundamental Rating

3

Taking everything into account, XLRN scores 3 out of 10 in our fundamental rating. XLRN was compared to 587 industry peers in the Biotechnology industry. XLRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, XLRN is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XLRN has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -32.35%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

XLRN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -226%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, XLRN has more shares outstanding
There is no outstanding debt for XLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 91.90 indicates that XLRN is not in any danger for bankruptcy at the moment.
There is no outstanding debt for XLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 91.9
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 12.14 indicates that XLRN has no problem at all paying its short term obligations.
A Quick Ratio of 12.14 indicates that XLRN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.14
Quick Ratio 12.14

More info and screens

5

3. Growth

3.1 Past

The earnings per share for XLRN have decreased strongly by -76.15% in the last year.
The Revenue has been growing slightly by 6.40% in the past year.
Measured over the past years, XLRN shows a very strong growth in Revenue. The Revenue has been growing by 38.58% on average per year.
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-75.76%
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y38.58%
Revenue growth Q2Q51.59%

3.2 Future

XLRN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.07% yearly.
XLRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.39% yearly.
EPS Next Y-41.56%
EPS Next 2Y-8.05%
EPS Next 3Y8.29%
EPS Next 5Y-3.07%
Revenue Next Year41.05%
Revenue Next 2Y47.46%
Revenue Next 3Y45.08%
Revenue Next 5Y45.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XLRN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -41

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.05%
EPS Next 3Y8.29%

More info and screens

0

5. Dividend

5.1 Amount

XLRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Acceleron Pharma

NASDAQ:XLRN (11/19/2021, 7:33:57 PM)

After market: 179.92 +1.17 (+0.65%)

178.75

-0.93 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.89B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.35%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -226%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 12.14
Quick Ratio 12.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-76.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-41.56%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.4%
Revenue growth 3Y90.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y